RE: Daewoong Pharmaceutical Co., Ltd. is strengthening its growth engine by investing 33 billion won, or28 Jul 2022 19:46
- Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in operating revenue in the second quarter due to the growth of ethical drugs and Nabota.
- A continuous increase in profitability is expected due to sales visualization of the new drug Fexuclue and Nabota's entry into the European market in the third quarter.